Intercept Pharmaceuticals Inc (ICPT): Rachel Mcminn , Chief Strategy Officer of Intercept Pharmaceuticals Inc sold 106 shares on Jul 5, 2016. The Insider selling transaction was reported by the company on Jul 7, 2016 to the Securities and Exchange Commission. The shares were sold at $145.11 per share for a total value of $15,381.58 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 7, 2016, Lisa Bright (officer ) sold 155 shares at $145.11 per share price.On May 4, 2016, Rachel Mcminn (Chief Strategy Officer) sold 130 shares at $147.49 per share price.Also, On Apr 7, 2016, Mark Pruzanski (CEO & President) sold 708 shares at $130.76 per share price.On Apr 6, 2016, David Shapiro (CMO and EVP – Development) sold 165 shares at $130.76 per share price.
Shares of Intercept Pharmaceuticals Inc (ICPT) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -2.89 points or -1.97% at $143.47 with 4,36,744 shares getting traded. Post opening the session at $145.56, the shares hit an intraday low of $142.45 and an intraday high of $147.29 and the price vacillated in this range throughout the day. The company has a market cap of $3,529 M and the number of outstanding shares has been calculated to be 2,45,95,270 shares. The 52-week high of Intercept Pharmaceuticals Inc is $285 and the 52-week low is $89.76.
Company has been under the radar of several Street Analysts.Intercept Pharmaceuticals Inc is Initiated by Cantor Fitzgerald to Sell and the brokerage firm has set the Price Target at $58. The Rating was issued on Jul 6, 2016.Intercept Pharmaceuticals Inc is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 239 from a previous price target of $423 . The Rating was issued on Jun 1, 2016.
Intercept Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate obeticholic acid (OCA) is a bile acid analog a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.